<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> is thought to arise from multiple genetic events that establish irreversible <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A different mechanism might be present in certain <z:mpath ids='MPATH_336'>leukaemias</z:mpath> initiated by a chromosomal translocation </plain></SENT>
<SENT sid="2" pm="."><plain>We have taken a new approach to determine if ablation of the genetic abnormality is sufficient for reversion by generating a conditional <z:e sem="disease" ids="C1519606" disease_type="Experimental Model of Disease" abbrv="">transgenic model</z:e> of BCR-ABL1 (also known as BCR-ABL)-induced <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>This oncogene is the result of a reciprocal translocation and is associated with different forms of <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>The most common form, p210 BCR-ABL1, is found in more than 90% of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) and in up to 15% of adult patients with de novoacute lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL) </plain></SENT>
<SENT sid="5" pm="."><plain>Efforts to establish a useful <z:e sem="disease" ids="C1519606" disease_type="Experimental Model of Disease" abbrv="">transgenic model</z:e> have been hampered by <z:mp ids='MP_0008762'>embryonic lethality</z:mp> when the oncogene is expressed during embryogenesis, by <z:hpo ids='HP_0003829'>reduced penetrance</z:hpo> or by extremely long latency periods </plain></SENT>
<SENT sid="6" pm="."><plain>One model uses the 'knock-in' approach to induce <z:mpath ids='MPATH_336'>leukaemia</z:mpath> by p190 BCR-ABL1(ref </plain></SENT>
<SENT sid="7" pm="."><plain>10) </plain></SENT>
<SENT sid="8" pm="."><plain>Given the limitations of models with p210, we used a different experimental approach </plain></SENT>
<SENT sid="9" pm="."><plain>Lethal <z:mpath ids='MPATH_336'>leukaemia</z:mpath> developed within an acceptable time frame in <z:hpo ids='HP_0000001'>all</z:hpo> animals, and complete remission was achieved by suppression of BCR-ABL1expression, even after multiple rounds of induction and reversion </plain></SENT>
<SENT sid="10" pm="."><plain>Our results demonstrate that BCR-ABL1is required for both induction and maintenance of <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
</text></document>